Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East

Author:

Ascierto Paolo Antonio1,Orlova Kristina2,Grignani Giovanni3,Dudzisz‐Śledź Monika4,Fenig Eyal5,Chiarion Sileni Vanna6,Fazio Nicola7,Samimi Mahtab8,Mortier Laurent9,Gebhardt Christoffer10,Kramkimel Nora11,Steven Neil12,Bechter Oliver13,Arance Ana14,Benincasa Elena15,Kostkova Lenka16,Costa Nuno17,Lorigan Paul18ORCID

Affiliation:

1. Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy Istituto Nazionale Tumori IRCCS Fondazione Pascale Naples Italy

2. FSBI “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation Moscow Russian Federation

3. Division of Medical Oncology Candiolo Cancer Institute, FPO—IRCCS, Candiolo Turin Italy

4. Department of Soft Tissue/Bone Sarcoma and Melanoma Maria Sklodowska‐Curie National Research Institute of Oncology Warsaw Poland

5. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

6. Istituto Oncologico Veneto ‐ IOV IRCCS Padova Italy

7. Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology (IEO), IRCCS Milan Italy

8. Dermatology Department University Hospital of Tours Tours France

9. Dermatology Clinic CARADERM and University of Lille, INSERM U1189, Lille Hospital–Claude Huriez Hospital Lille Cedex France

10. Department of Dermatology and Venereology University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

11. Department of Dermatology Hôpital Cochin, AP‐HP Paris France

12. Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK

13. Department of General Medical Oncology University Hospitals Leuven, KU Leuven Leuven Belgium

14. Department of Medical Oncology Hospital Clínic Barcelona Spain

15. The healthcare business of Merck KGaA Darmstadt Germany

16. Merck spol. s r.o., Bratislava, Slovakia, an affiliate of Merck KGaA Darmstadt Germany

17. Pfizer Inc. Porto Salvo Portugal

18. Division of Cancer Sciences University of Manchester and the Christie NHS Foundation Trust Manchester UK

Funder

Merck KGaA

Publisher

Wiley

Subject

Cancer Research,Oncology

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3